Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 10/2008

01-10-2008 | Article

Serological microarray for a paradoxical diagnostic of Whipple’s disease

Authors: C. J. Bonhomme, P. Renesto, S. Nandi, A. M. Lynn, D. Raoult

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 10/2008

Login to get access

Abstract

Whipple’s disease is a systemic chronic infection caused by Tropheryma whipplei. Asymptomatic people may carry T. whipplei in their digestive tract and this can be determined by PCR, making serological diagnosis useful to distinguish between carriers and patients. Putative antigenic proteins were selected by computational analysis of the T. whipplei genome, immunoproteomics studies and from literature. After expression, putative T. whipplei antigens were screened by microimmunofluorescence with sera of immunized rabbit. Selected targets were screened by microarray using sera from patients and carriers. Paradoxically, with 19 tested recombinant proteins and a glycosylated native protein of T. whipplei, a higher immune response was observed with asymptomatic carriers. In contrast, quantification of human IgA exhibited a higher reaction in patients than in carriers against 10 antigens. These results were used to design a diagnostic test with a cut-off value for each antigen. A blind test assay was performed and was able to diagnose 6/8 patients and 11/12 carriers. Among people with positive T. whipplei PCR of the stool, patients differ from carriers by having positive IgA detection and a negative IgG detection. If confirmed, this serological test will distinguish between carriers and patients in people with positive PCR of the stool.
Literature
1.
go back to reference La Scola B, Fenollar F, Fournier PE, Altwegg M, Mallet MN, Raoult D (2001) Description of Tropheryma whipplei gen.nov., sp.nov., the Whipple’s disease bacillus. Int J Syst Evol Microbiol 51:1471–1479PubMed La Scola B, Fenollar F, Fournier PE, Altwegg M, Mallet MN, Raoult D (2001) Description of Tropheryma whipplei gen.nov., sp.nov., the Whipple’s disease bacillus. Int J Syst Evol Microbiol 51:1471–1479PubMed
2.
go back to reference Wilson KH, Blitchington R, Frothingham R, Wilson JA (1991) Phylogeny of the WhippIe’s-disease-associated bacterium. Lancet 338:474–475PubMedCrossRef Wilson KH, Blitchington R, Frothingham R, Wilson JA (1991) Phylogeny of the WhippIe’s-disease-associated bacterium. Lancet 338:474–475PubMedCrossRef
3.
go back to reference Relman DA, Schmidt TM, MacDermott RP, Falkow S (1992) Identification of the uncultured bacillus of Whipple’s disease. N Engl J Med 327:293–301PubMed Relman DA, Schmidt TM, MacDermott RP, Falkow S (1992) Identification of the uncultured bacillus of Whipple’s disease. N Engl J Med 327:293–301PubMed
4.
go back to reference Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, Lepidi H, Roux V, Piette JC, Vandenesch F, Vital Durand D, Marrie TJ (2000) Cultivation of the bacillus of Whipple’s disease. New Engl J Med 342:620–625PubMedCrossRef Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, Lepidi H, Roux V, Piette JC, Vandenesch F, Vital Durand D, Marrie TJ (2000) Cultivation of the bacillus of Whipple’s disease. New Engl J Med 342:620–625PubMedCrossRef
5.
go back to reference Renesto P, Crapoulet N, Ogata H, La Scola B, Vestris G, Claverie JM, Raoult D (2003) Genome-based design of a cell-free culture medium for Tropheryma whipplei. Lancet 362:447–449PubMedCrossRef Renesto P, Crapoulet N, Ogata H, La Scola B, Vestris G, Claverie JM, Raoult D (2003) Genome-based design of a cell-free culture medium for Tropheryma whipplei. Lancet 362:447–449PubMedCrossRef
6.
go back to reference Bentley SD, Maiwald M, Murphy LD, Pallen MJ, Yeats CA, Dover LG, Norbertczak HT, Besra GS, Quail MA, Harris DE, Von Herbay A, Goble A, Rutter S, Squares R, Squares S, Barrell BG, Parkhill J, Relman DA (2003) Sequencing and analysis of the genome of the Whipple’s disease bacterium Tropheryma whipplei. Lancet 361:637–644PubMedCrossRef Bentley SD, Maiwald M, Murphy LD, Pallen MJ, Yeats CA, Dover LG, Norbertczak HT, Besra GS, Quail MA, Harris DE, Von Herbay A, Goble A, Rutter S, Squares R, Squares S, Barrell BG, Parkhill J, Relman DA (2003) Sequencing and analysis of the genome of the Whipple’s disease bacterium Tropheryma whipplei. Lancet 361:637–644PubMedCrossRef
7.
go back to reference Raoult D, Ogata H, Audic S, Robert C, Suhre K, Drancourt M, Claverie JM (2003) Tropheryma whipplei twist: a human pathogenic actinobacteria with a reduced genome. Genome Res 13:1800–1809PubMed Raoult D, Ogata H, Audic S, Robert C, Suhre K, Drancourt M, Claverie JM (2003) Tropheryma whipplei twist: a human pathogenic actinobacteria with a reduced genome. Genome Res 13:1800–1809PubMed
8.
go back to reference Kowalczewska M, Fenollar F, Lafitte D, Raoult D (2006) Identification of candidate antigen in Whipple’s disease using a serological proteomic approach. Proteomics 6:3294–3305PubMedCrossRef Kowalczewska M, Fenollar F, Lafitte D, Raoult D (2006) Identification of candidate antigen in Whipple’s disease using a serological proteomic approach. Proteomics 6:3294–3305PubMedCrossRef
11.
12.
go back to reference Maiwald M, Relman D (2001) Whipple’s disease and Tropheryma whippelii: secrets slowly revealed. Clin Infect Dis 32:457–463PubMedCrossRef Maiwald M, Relman D (2001) Whipple’s disease and Tropheryma whippelii: secrets slowly revealed. Clin Infect Dis 32:457–463PubMedCrossRef
13.
go back to reference Mahnel R, Marth T (2004) Progress, problems, and perspectives in diagnosis and treatment of Whipple’s disease. Clin Exp Med 4:39–43PubMedCrossRef Mahnel R, Marth T (2004) Progress, problems, and perspectives in diagnosis and treatment of Whipple’s disease. Clin Exp Med 4:39–43PubMedCrossRef
14.
go back to reference Black-Schaffer B (1949) The tinctoral demonstration of a glycoprotein in Whipple’s disease. Proc Soc Exp Biol 72:225–227 Black-Schaffer B (1949) The tinctoral demonstration of a glycoprotein in Whipple’s disease. Proc Soc Exp Biol 72:225–227
16.
go back to reference Schoniger-Hekele M, Petermann D, Weber B, Muller C (2007) Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers. Appl Environ Microbiol 73:2033–2035PubMedCrossRef Schoniger-Hekele M, Petermann D, Weber B, Muller C (2007) Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers. Appl Environ Microbiol 73:2033–2035PubMedCrossRef
17.
go back to reference Fenollar F, Trani M, Davoust B, Salle B, Birg ML, Rolain JM, Raoult D (2008) Carriage of Tropheryma whipplei in stools of sewer workers and human controls, but not in monkeys and apes. J Infect Dis In press Fenollar F, Trani M, Davoust B, Salle B, Birg ML, Rolain JM, Raoult D (2008) Carriage of Tropheryma whipplei in stools of sewer workers and human controls, but not in monkeys and apes. J Infect Dis In press
18.
go back to reference Li W, Fenollar F, Rolain JM, Fournier PE, Feurle GE, Muller C, Moos A, Marth T, Altwegg M, Calligaris-Maibach R, Schneider T, Biagi F, La Scola B, Raoult D (2008) Genotyping reveals a wide heterogeneity of Tropheryma whipplei. Microbiology 154:527 Li W, Fenollar F, Rolain JM, Fournier PE, Feurle GE, Muller C, Moos A, Marth T, Altwegg M, Calligaris-Maibach R, Schneider T, Biagi F, La Scola B, Raoult D (2008) Genotyping reveals a wide heterogeneity of Tropheryma whipplei. Microbiology 154:527
19.
go back to reference Desnues B, Raoult D, Mege JL (2005) IL-16 is critical for Tropheryma whipplei replication in Whipple’s disease. J Immunol 175:4575–4582PubMed Desnues B, Raoult D, Mege JL (2005) IL-16 is critical for Tropheryma whipplei replication in Whipple’s disease. J Immunol 175:4575–4582PubMed
20.
go back to reference Desnues B, Ihrig M, Raoult D, Mege JL (2006) Whipple’s disease: a macrophage disease. Clin Vaccine Immunol 13:170–178PubMedCrossRef Desnues B, Ihrig M, Raoult D, Mege JL (2006) Whipple’s disease: a macrophage disease. Clin Vaccine Immunol 13:170–178PubMedCrossRef
21.
go back to reference Benoit M, Fenollar F, Raoult D, Mege JL (2007) Increased levels of circulating IL-16 and apoptosis markers are related to the activity of Whipple’s Disease. PLoS ONE 2:e494PubMedCrossRef Benoit M, Fenollar F, Raoult D, Mege JL (2007) Increased levels of circulating IL-16 and apoptosis markers are related to the activity of Whipple’s Disease. PLoS ONE 2:e494PubMedCrossRef
22.
go back to reference Kowalczewska M, Fenollar F, Villard C, Azza S, Roux M, Raoult D (2008) An immunoproteomic approach for identification of clinical biomarkers of Whipple’s disease. Proteomics Clin Appl In press Kowalczewska M, Fenollar F, Villard C, Azza S, Roux M, Raoult D (2008) An immunoproteomic approach for identification of clinical biomarkers of Whipple’s disease. Proteomics Clin Appl In press
23.
go back to reference Bacarese-Hamilton T, Bistoni F, Crisanti A (2002) Protein microarrays: from serodiagnosis to whole proteome scale analysis of the immune response against pathogenic microorganisms. Biotechniques Suppl:S24-S29 Bacarese-Hamilton T, Bistoni F, Crisanti A (2002) Protein microarrays: from serodiagnosis to whole proteome scale analysis of the immune response against pathogenic microorganisms. Biotechniques Suppl:S24-S29
24.
go back to reference Mezzasoma L, Bacarese-Hamilton T, Di Cristina M, Rossi R, Bistoni F, Crisanti A (2002) Antigen microarrays for serodiagnosis of infectious diseases. Clin Chem 48:121–130PubMed Mezzasoma L, Bacarese-Hamilton T, Di Cristina M, Rossi R, Bistoni F, Crisanti A (2002) Antigen microarrays for serodiagnosis of infectious diseases. Clin Chem 48:121–130PubMed
25.
go back to reference Steller S, Angenendt P, Cahill DJ, Heuberger S, Lehrach H, Kreutzberger J (2005) Bacterial protein microarrays for identification of new potential diagnostic markers for Neisseria meningitidis infections. Proteomics 5:2048–2055PubMedCrossRef Steller S, Angenendt P, Cahill DJ, Heuberger S, Lehrach H, Kreutzberger J (2005) Bacterial protein microarrays for identification of new potential diagnostic markers for Neisseria meningitidis infections. Proteomics 5:2048–2055PubMedCrossRef
26.
go back to reference Bonhomme CJ, Nappez C, Raoult D (2007) Microarray for serotyping of Bartonella species. BMC Microbiol 7:59PubMedCrossRef Bonhomme CJ, Nappez C, Raoult D (2007) Microarray for serotyping of Bartonella species. BMC Microbiol 7:59PubMedCrossRef
27.
go back to reference Gouriet F, Drancourt M, Raoult D (2006) Multiplexed serology in atypical bacterial pneumonia. Ann N Y Acad Sci 1078:530–540PubMedCrossRef Gouriet F, Drancourt M, Raoult D (2006) Multiplexed serology in atypical bacterial pneumonia. Ann N Y Acad Sci 1078:530–540PubMedCrossRef
28.
go back to reference Saha S, Raghava GPS (2004) BcePred: Prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. In: Nicosia G, Cutello V, Bentley PJ, Timmis J (eds) ICARIS, LNCS. Springer, pp 197–204 Saha S, Raghava GPS (2004) BcePred: Prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. In: Nicosia G, Cutello V, Bentley PJ, Timmis J (eds) ICARIS, LNCS. Springer, pp 197–204
29.
go back to reference Rolain JM, Lecam C, Raoult D (2003) Simplified serological diagnosis of endocarditis due to Coxiella burnetii and Bartonella. Clin Diagn Lab Immunol 10:1147–1148PubMedCrossRef Rolain JM, Lecam C, Raoult D (2003) Simplified serological diagnosis of endocarditis due to Coxiella burnetii and Bartonella. Clin Diagn Lab Immunol 10:1147–1148PubMedCrossRef
30.
go back to reference Eshaghi S, Hedren M, Nasser MI, Hammarberg T, Thornell A, Nordlund P (2005) An efficient strategy for high-throughput expression screening of recombinant integral membrane proteins. Protein Sci 14:676–683PubMedCrossRef Eshaghi S, Hedren M, Nasser MI, Hammarberg T, Thornell A, Nordlund P (2005) An efficient strategy for high-throughput expression screening of recombinant integral membrane proteins. Protein Sci 14:676–683PubMedCrossRef
31.
go back to reference Sagara K, Matsuyama S, Mizushima S (1994) SecF stabilizes SecD and SecY, components of the protein translocation machinery of the Escherichia coli cytoplasmic membrane. J Bacteriol 176:4111–4116PubMed Sagara K, Matsuyama S, Mizushima S (1994) SecF stabilizes SecD and SecY, components of the protein translocation machinery of the Escherichia coli cytoplasmic membrane. J Bacteriol 176:4111–4116PubMed
32.
go back to reference Gouriet F, Levy PY, Samson L, Drancourt M, Raoult D (2008) Comparison of multiplexed slides InoDiag automate immunofluorescence to reference serology in the diagnosis of atypical bacterial pneumonia. Clin Microbiol Infect submitted Gouriet F, Levy PY, Samson L, Drancourt M, Raoult D (2008) Comparison of multiplexed slides InoDiag automate immunofluorescence to reference serology in the diagnosis of atypical bacterial pneumonia. Clin Microbiol Infect submitted
34.
go back to reference Walhout AJ, Temple GF, Brasch MA, Hartley JL, Lorson MA, van den Heuvel S, Vidal M (2000) GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes. Methods Enzymol 328:575–592PubMedCrossRef Walhout AJ, Temple GF, Brasch MA, Hartley JL, Lorson MA, van den Heuvel S, Vidal M (2000) GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes. Methods Enzymol 328:575–592PubMedCrossRef
35.
go back to reference Lepidi H, Fenollar F, Gerolami R, Mege JL, Bonzi MF, Chappuis M, Sahel J, Raoult D (2003) Whipple’s disease: Immunospecific and quantitative immunohistochemical study of intestinal biopsy specimens. Hum Pathol 34:589–596PubMedCrossRef Lepidi H, Fenollar F, Gerolami R, Mege JL, Bonzi MF, Chappuis M, Sahel J, Raoult D (2003) Whipple’s disease: Immunospecific and quantitative immunohistochemical study of intestinal biopsy specimens. Hum Pathol 34:589–596PubMedCrossRef
36.
go back to reference Eshaghi S, Hedren M, Nasser MI, Hammarberg T, Thornell A, Nordlund P (2005) An efficient strategy for high-throughput expression screening of recombinant integral membrane proteins. Protein Sci 14:676–683PubMedCrossRef Eshaghi S, Hedren M, Nasser MI, Hammarberg T, Thornell A, Nordlund P (2005) An efficient strategy for high-throughput expression screening of recombinant integral membrane proteins. Protein Sci 14:676–683PubMedCrossRef
37.
go back to reference Kalt A, Schneider T, Ring S, Hoffmann J, Zeitz M, Stallmach A, Persing DH, Marth T (2006) Decreased levels of interleukin-12p40 in the serum of patients with Whipple’s disease. Int J Colorectal Dis 21:114–120PubMedCrossRef Kalt A, Schneider T, Ring S, Hoffmann J, Zeitz M, Stallmach A, Persing DH, Marth T (2006) Decreased levels of interleukin-12p40 in the serum of patients with Whipple’s disease. Int J Colorectal Dis 21:114–120PubMedCrossRef
38.
go back to reference Mahnel R, Kalt A, Ring S, Stallmach A, Strober W, Marth T (2005) Immunosuppressive therapy in Whipple’s disease patients is associated with the appearance of gastrointestinal manifestations. Am J Gastroenterol 100:1167–1173PubMedCrossRef Mahnel R, Kalt A, Ring S, Stallmach A, Strober W, Marth T (2005) Immunosuppressive therapy in Whipple’s disease patients is associated with the appearance of gastrointestinal manifestations. Am J Gastroenterol 100:1167–1173PubMedCrossRef
Metadata
Title
Serological microarray for a paradoxical diagnostic of Whipple’s disease
Authors
C. J. Bonhomme
P. Renesto
S. Nandi
A. M. Lynn
D. Raoult
Publication date
01-10-2008
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 10/2008
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-008-0528-0

Other articles of this Issue 10/2008

European Journal of Clinical Microbiology & Infectious Diseases 10/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine